The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

Mark S. De Souza*, Silvia Ratto-Kim, Weerawan Chuenarom, Alexandra Schuetz, Somsak Chantakulkij, Bessara Nuntapinit, Anais Valencia-Micolta, Doris Thelian, Sorachai Nitayaphan, Punnee Pitisuttithum, Robert M. Paris, Jaranit Kaewkungwal, Nelson L. Michael, Supachai Rerks-Ngarm, Bonnie Mathieson, Mary Marovich, Jeffrey R. Currier, Jerome H. Kim, Supamit Chunsuttiwat, Nakorn PremsriChawetsan Namwat, Prayura Kunasol, Prasert Thongcharoen, Chirasak Khamboonruang, Valai Bussaratid, Wirach Maek-a-nantawat, Jittima Dhitavat, Pravan Suntharasamai, Swangjai Pungpak, Siriwan Vanijanonta, Jaranit Kaewkunwal, Amnat Khamsiriwatchara, Pawinee Jarujareet, Chirapa Easmila, Suchana Tabprasit, Viseth Ngauy, Robert Paris, Michael Benenson, Patricia Morgan, Arthur Brown, Mark De Souza, Rapee Trichavaroj, Nusara Thaitawat, Kanyasiri Kongnonkok, Boot Keawboon, Yuwadee Phuang-Ngern, Susan Mason, Sanjay Gurunathan, Jim Tartaglia, John G. McNeil, Robin Harkness, Claude Meric, Lynn Baglyos, Raphaelle El Habib, Don Francis, Carter Lee, Elizabeth Adams, Merlin L. Robb, Mark Milazzo, Amy Bolen, Beryl Wessner, Jeffrey Currier, Deborah L. Birx, Don Stablein, Terry Germanson, Len Dally, Jean Louis Excler, Jeffrey Berenberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Fingerprint

Dive into the research topics of 'The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope'. Together they form a unique fingerprint.

Medicine & Life Sciences